Clinical Trials for Non Small Cell Lung Cancer

Find clinical trials for non small cell lung cancer. Discover research opportunities and treatment options in your area.

255 Active Trials Found

Showing 255 trials on this page

Page 1 of 13

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

NCT ID: NCT06694454

This clinical trial is studying a new treatment approach for early-stage non-small cell lung cancer (NSCLC), which is the most common type of lung cancer. Researchers want to see if inhaling a drug...

Not yet recruiting

Phase: PHASE1 Type: interventional Locations: Bethesda, Maryland, United States

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

NCT ID: NCT06312137

This clinical trial is investigating whether a combination of two treatments, pembrolizumab and sacituzumab tirumotecan, can help patients with a type of lung cancer called non-small cell lung canc...

Clinical Trials for Non Small Cell Lung Cancer

255 Active Trials Found

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer

POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC

A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway

A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Combination Study of Guadecitabine/ASTX727 and Pembrolizumab

A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

Implementing Circulating Tumor DNA Analysis at Initial Diagnosis to Improve Management of Advanced NSCLC Patients

A Study of MGC026 in Participants With Advanced Solid Tumors

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer

Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

STK-012 Monotherapy and in Combination Therapy in Patients With Solid Tumors

Effect of G-CSF on MDSC and Cancer Stem-cells Interactions in Non-small Cell Lung Cancers (CIRCUIT)

Related Conditions